| Source: |
| Type: |
| Enzymes involved in regulating gene expression by removing acetyl groups from histones, the proteins around which DNA is wrapped. -Many cancers exhibit altered expression levels of HDACs, which can contribute to the dysregulation of genes involved in cell growth, survival, and differentiation. -HDACs can repress the expression of tumor suppressor genes, leading to uncontrolled cell proliferation and survival. This repression can be a key factor in the development and progression of cancer. -HDAC inhibitors (HDACi) have been developed and are being investigated for their ability to reactivate silenced genes, induce cell cycle arrest, and promote apoptosis in cancer cells. -HDAC1, HDAC2): Often overexpressed in various cancers, including breast, prostate, and colorectal cancers. Their overexpression is associated with poor prognosis. -HDAC4, HDAC5): These may have both oncogenic and tumor-suppressive roles depending on the context and cancer type. -While HDACs are not classified as traditional oncogenes, their overexpression and activity can contribute to oncogenic processes. -HDAC inhibitor works by preventing the removal of acetyl groups from histones, thereby modulating gene expression, influencing cell behavior, and potentially reversing aberrant gene silencing seen in various diseases. -HDAC inhibitors can help reactivate these genes, thereby inhibiting growth and inducing apoptosis in cancer cells. |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 1062- | SSE, | Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | U87MG |
| 2353- | TQ, | The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies |
| - | Review, | PC, | NA |
| 2119- | TQ, | Dual properties of Nigella Sativa: anti-oxidant and pro-oxidant |
| - | Review, | Var, | NA |
| 2100- | TQ, | Dual properties of Nigella Sative: Anti-oxidant and Pro-oxidant |
| - | Review, | Var, | NA |
| 2101- | TQ, | HDAC inhibition by Nigella sativa L. sprouts extract in hepatocellular carcinoma: an approach to study anti-cancer potential |
| - | Study, | HCC, | NA |
| 2102- | TQ, | A review on therapeutic potential of Nigella sativa: A miracle herb |
| - | Review, | Var, | NA |
| 2103- | TQ, | Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells |
| - | in-vitro, | PC, | Hs766t | - | in-vitro, | PC, | MIA PaCa-2 |
| 2105- | TQ, | Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation |
| - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | Hs766t | - | in-vivo, | NA, | NA |
| 2108- | TQ, | Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa |
| - | Review, | Var, | NA |
| 3407- | TQ, | Thymoquinone and its pharmacological perspective: A review |
| - | Review, | Var, | NA |
| 3422- | TQ, | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
| - | Review, | Var, | NA |
| 3425- | TQ, | Advances in research on the relationship between thymoquinone and pancreatic cancer |
| - | in-vitro, | PC, | NA |
| 3426- | TQ, | Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | AML, | JK |
| 3423- | TQ, | Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics |
| - | Review, | Var, | NA |
| 3421- | TQ, | Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer |
| - | Analysis, | Nor, | NA | - | in-vivo, | Nor, | NA | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | HaCaT |
| 9125- | ZYF, | Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 9124- | ZYF, | Zyflamend, a combination of herbal extracts, attenuates tumor growth in murine xenograft models of prostate cancer |
| - | in-vitro, | Pca, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:140 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid